Enanta Pharmaceuticals
ENTA
112 hedge funds and large institutions have $409M invested in Enanta Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 48 increasing their positions, 28 reducing their positions, and 11 closing their positions.
118% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 11
71% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 28
13% more funds holding
Funds holding: 99 → 112 (+13)
3% less capital invested
Capital invested by funds: $419M → $409M (-$10.9M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
29% less call options, than puts
Call options by funds: $1.15M | Put options by funds: $1.62M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$12.5M |
| 2 |
SAM
Senzar Asset Management
New York
|
+$12.4M |
| 3 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$7.68M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$4.92M |
| 5 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$4.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$51.4M |
| 2 |
WSA
Wall Street Associates
Lajolla,
California
|
-$2.4M |
| 3 |
AAM
Aureus Asset Management
Boston,
Massachusetts
|
-$2.39M |
| 4 |
CCM
Cadence Capital Management
Boston,
Massachusetts
|
-$2.38M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
-$1.62M |
ENTA Hedge Fund Activity: Q3 2014 in Review
112 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q3 2014, worth a combined $409M — down 2.6% from $419M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new ENTA positions and 11 closed out — a net gain of 13 holders — while 48 added to existing stakes and 28 trimmed.
The largest buyer was Marshall Wace, adding an estimated $12.5M. The largest seller was RA Capital Management, cutting an estimated $51.4M.
- 112 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q3 2014, up from 99 in Q2 2014.
- Funds reported $409M of Enanta Pharmaceuticals stock for Q3 2014, down 2.6% quarter-over-quarter.
- 24 funds opened new Enanta Pharmaceuticals positions in Q3 2014 and 11 closed out, a net change of +13 holders.
- The largest Enanta Pharmaceuticals buyer in Q3 2014 was Marshall Wace, an estimated $12.5M added.
- The largest Enanta Pharmaceuticals seller in Q3 2014 was RA Capital Management, an estimated $51.4M sold.
Based on aggregated 13F filings for Q3 2014.